These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27334945)

  • 21. Disclosing tau tangles using PET imaging: a pharmacological review of the radiotracers available in 2021.
    Van Wambeke É; Gérard T; Lhommel R; Hanseeuw B
    Acta Neurol Belg; 2022 Apr; 122(2):263-272. PubMed ID: 34713414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tau imaging in neurodegenerative diseases.
    Dani M; Brooks DJ; Edison P
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1139-50. PubMed ID: 26572762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases.
    Dupont AC; Largeau B; Santiago Ribeiro MJ; Guilloteau D; Tronel C; Arlicot N
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28387722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of Tau and α-Synuclein Pathology in the Visual System.
    Rahimi J; Milenkovic I; Kovacs GG
    J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias.
    Wren MC; Lashley T; Årstad E; Sander K
    Acta Neuropathol Commun; 2018 May; 6(1):34. PubMed ID: 29716656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New molecular targets for PET and SPECT imaging in neurodegenerative diseases.
    Benadiba M; Luurtsema G; Wichert-Ana L; Buchpigel CA; Busatto Filho G
    Braz J Psychiatry; 2012 Oct; 34 Suppl 2():S125-36. PubMed ID: 23429844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.
    Heurling K; Ashton NJ; Leuzy A; Zimmer ER; Blennow K; Zetterberg H; Eriksson J; Lubberink M; Schöll M
    Mol Cell Neurosci; 2019 Jun; 97():34-42. PubMed ID: 30796959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
    Ishikawa A; Tokunaga M; Maeda J; Minamihisamatsu T; Shimojo M; Takuwa H; Ono M; Ni R; Hirano S; Kuwabara S; Ji B; Zhang MR; Aoki I; Suhara T; Higuchi M; Sahara N
    J Alzheimers Dis; 2018; 61(3):1037-1052. PubMed ID: 29332041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tracer development for PET imaging of proteinopathies.
    Kallinen A; Kassiou M
    Nucl Med Biol; 2022; 114-115():108-120. PubMed ID: 35487833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concepts and classification of neurodegenerative diseases.
    Kovacs GG
    Handb Clin Neurol; 2017; 145():301-307. PubMed ID: 28987178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tau PET imaging: present and future directions.
    Saint-Aubert L; Lemoine L; Chiotis K; Leuzy A; Rodriguez-Vieitez E; Nordberg A
    Mol Neurodegener; 2017 Feb; 12(1):19. PubMed ID: 28219440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders.
    Lopez-Cuina M; Meissner WG
    Rev Neurol (Paris); 2022 May; 178(5):460-471. PubMed ID: 35562199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Abeta, tau and alpha-synuclein and glial cells].
    Akiyama H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2006 Feb; 26(1):23-31. PubMed ID: 16637593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroinflammation in Neurodegenerative Diseases: Current Multi-modal Imaging Studies and Future Opportunities for Hybrid PET/MRI.
    Aiello M; Cavaliere C; Fiorenza D; Duggento A; Passamonti L; Toschi N
    Neuroscience; 2019 Apr; 403():125-135. PubMed ID: 30071279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
    Melki R
    J Parkinsons Dis; 2015; 5(2):217-27. PubMed ID: 25757830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention.
    Briston T; Hicks AR
    Biochem Soc Trans; 2018 Aug; 46(4):829-842. PubMed ID: 29986938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.
    Leinonen V; Rauramaa T; Johansson J; Bottelbergs A; Tesseur I; van der Ark P; Pemberton D; Koivisto AM; Jääskeläinen JE; Hiltunen M; Herukka SK; Blennow K; Zetterberg H; Jokinen P; Rokka J; Helin S; Haaparanta-Solin M; Solin O; Okamura N; Kolb HC; Rinne JO
    J Alzheimers Dis; 2018; 64(1):171-179. PubMed ID: 29865068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glial contributions to neurodegeneration in tauopathies.
    Leyns CEG; Holtzman DM
    Mol Neurodegener; 2017 Jun; 12(1):50. PubMed ID: 28662669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date.
    Lee BG; Leavitt MJ; Bernick CB; Leger GC; Rabinovici G; Banks SJ
    J Neurotrauma; 2018 Sep; 35(17):2015-2024. PubMed ID: 29609516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration.
    Katsinelos T; Tuck BJ; Mukadam AS; McEwan WA
    Front Immunol; 2019; 10():1139. PubMed ID: 31214163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.